Palisade Bio (PALI) News Today $2.44 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)November 21 at 8:15 AM | globenewswire.comPalisade Bio initiated with a Buy at BrooklineNovember 20 at 10:56 PM | markets.businessinsider.comPalisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) SummitNovember 14, 2024 | markets.businessinsider.comPalisade Bio price target lowered to $8 from $22.50 at MaximNovember 14, 2024 | markets.businessinsider.comPalisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108November 12, 2024 | globenewswire.comPalisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)November 7, 2024 | markets.businessinsider.comPalisade Bio announces data from two ex vivo studies of PALI-2108November 2, 2024 | markets.businessinsider.comPalisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative ColitisOctober 31, 2024 | globenewswire.comBuy Rating for Palisade Bio Amid Novel UC Treatment Potential and Health Canada Trial ApprovalOctober 12, 2024 | markets.businessinsider.comPalisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)October 10, 2024 | globenewswire.comPalisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCOctober 8, 2024 | finance.yahoo.comPalisade Bio (NASDAQ:PALI) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.comPalisade Bio (NASDAQ:PALI) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comEternal Strands - Official Setting TrailerSeptember 21, 2024 | msn.comPalisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision TherapiesSeptember 16, 2024 | markets.businessinsider.comBuy Rating on Palisade Bio Amidst UC Treatment Breakthrough and Strong Market PotentialSeptember 7, 2024 | markets.businessinsider.comPalisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient StratificationSeptember 5, 2024 | markets.businessinsider.comPalisade Bio, Inc.: Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deGalectin Flat on Quarterly FiguresAugust 13, 2024 | baystreet.caPalisade Bio Edges up on Q2 ResultsAugust 13, 2024 | baystreet.caPalisade Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | globenewswire.comPalisade Bio, Inc.: Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative ColitisAugust 10, 2024 | finanznachrichten.dePalisade Bio sets dose for Phase 1 ulcerative colitis drug trialAugust 10, 2024 | uk.investing.comPalisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative ColitisAugust 8, 2024 | globenewswire.comPalisade Bio Participates in Virtual Investor “What this Means” SegmentJuly 31, 2024 | globenewswire.comPalisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108July 29, 2024 | globenewswire.comPalisade Bio, Inc.: Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108July 19, 2024 | finanznachrichten.dePalisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108July 19, 2024 | globenewswire.comPalisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug ProductJuly 11, 2024 | globenewswire.comPalisade Bio to Participate in the Virtual Investor Closing Bell SeriesJune 24, 2024 | globenewswire.comPalisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life SciencesJune 21, 2024 | globenewswire.comPalisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108June 11, 2024 | globenewswire.comPalisade Bio to Present at the Virtual Investor Pitch ConferenceJune 10, 2024 | globenewswire.comPalisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse ModelsMay 21, 2024 | finance.yahoo.comPalisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse ModelsMay 21, 2024 | globenewswire.comPalisade Bio, Inc. (PALI)May 19, 2024 | finance.yahoo.comBuy Rating Affirmed for Palisade Bio’s PALI-2108 Amid Strong Financials and Promising PartnershipMay 17, 2024 | markets.businessinsider.comPalisade Bio GAAP EPS of -$4.59May 14, 2024 | seekingalpha.comPalisade Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 14, 2024 | globenewswire.comPALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024May 14, 2024 | msn.comPalisade Bio Appoints Margery Fischbein to its Board of DirectorsMay 7, 2024 | globenewswire.comPalisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesMay 7, 2024 | globenewswire.comPalisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesMay 2, 2024 | globenewswire.comMarijuana reclassified federally in major win for the legal cannabis industryMay 1, 2024 | msn.comPalisade Bio stock rallies 50% premarket on colitis drug updateMay 1, 2024 | msn.comPalisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)May 1, 2024 | finance.yahoo.comTrading was temporarily halted for "PALI" at 09:05 AM with a stated reason of "LULD pause."May 1, 2024 | marketbeat.comPalisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)May 1, 2024 | globenewswire.comPalisade Bio, Strand Life Sciences team up on colitis drug researchApril 23, 2024 | msn.comWhy Palisade Bio Stock Is Up TodayApril 23, 2024 | msn.com Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. PALI Media Mentions By Week PALI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PALI News Sentiment▼0.150.48▲Average Medical News Sentiment PALI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PALI Articles This Week▼32▲PALI Articles Average Week Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PSTV News NLSP News SNSE News AWH News NKGN News TLPH News EGRX News TSBX News IPA News INDP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PALI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
